TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06094101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine IPX
Description: Peptide vaccine is a combination of~1. class II peptide spanning the sarcoma-specific fusion-breakpoint (fusion-peptide)~2. class-II neopeptide based on a patient-individual nonsynonymous mutation with a high immunogenicity (mutation-based neopeptide).~3. control peptide derived from Survivin.~4. adjuvant: toll like receptor (TLR) 1/2 ligand XS15.
Study: NCT06343376

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRt/19-28z/IL-12 CAR T-lymphocytes
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGFRt/19-28z/IL-12 CAR T-lymphocytes
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study: NCT06648291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QOCA EKG Device
Description: The investigators scheduled telephone interviews every three days to encourage and monitor the development of good self-health care behaviors by: (1) asking about daily blood pressure, weight, and lower extremity edema; (2) providing medication counseling, as well as exercise and dietary hygiene recommendations; (3) offering wound care guidance; (4) advising on the proper use of wounds; (5) advising on avoiding cardiac risk factors such as smoking and secondhand smoke; and (6) following up on physical status at outpatient clinics and assisting with referrals to relevant clinics, such as nutrition or rehabilitation, based on the patient's condition. A QOCA portable electrocardiogram (ECG) measurement device will be provided for patients to use at home. In the event of abnormal physiological values, the investigator will contact the patient to assess his or her medical status and provide 24-hour online counseling.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Provide post-operative education on the day of discharge and follow up with a phone call one week after discharge to check on the patient.
Study: NCT05189496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: hyperbaric oxygen therapy
Study: NCT05691491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given orally (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib
Description: Given PO
Study: NCT01189734

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: laparoscopic common bile duct exploration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy
Study: NCT05061017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixatimod
Description: Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pixatimod
Description: Pixatimod is an investigational drug that is being evaluated in studies involving melanoma, non-small cell lung cancer, and microsatellite stable colorectal cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is approved by the FDA for the treatment of melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of head/neck, urothelial carcinoma, MSI-H colorectal cancer, hepatocellular carcinoma, gastric carcinoma and gastroesophageal junction (GEJ) cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (low dose)
Description: Cyclophosphamide is approved by the FDA for the treatment of acute lymphoblastic leukemia, acute monocytic leukemia, acute myeloid leukemia, breast cancer, chronic granulocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, multiple myeloma, mycosis fungoides, neuroblastoma, non-Hodgkin lymphoma, ovarian cancer, retinoblastoma. Low-dose (immunomodulatory) cyclophosphamide is being studied in combination with various types of immunotherapy including nivolumab and pembrolizumab
Study: NCT04912219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.~Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.~Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.~This will be repeated for a total of four treatments one month apart
Study: NCT06355167

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bacopa monnieri
Description: Daily oral intake of Bacopa monnieri during 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bacopa monnieri
Description: Daily oral intake of Bacopa monnieri during 6 weeks
Study: NCT04685668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The PartoMa guidelines and training
Description: All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics in five study sites during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.~The intervention includes the following two components:~1. Implementation of a pocket booklet with simple and locally achievable clinical guidance for safe and respectful care at birth developed by the research team and birth attendants at the five hospital study sites;~2. Quarterly, the birth attendants will be offered training in the use of the booklet in 3-hour case-based seminars.
Study: NCT06528795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scenario-based high-reality hybrid simulation method
Description: Intervention group students will be practiced with the Lactation Simulator, a high-reality simulator, in the simulation laboratory, accompanied by a scenario.
Study: NCT05405660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: barzolvolimab
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Subcutaneous Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Subcutaneous Administration
Study: NCT04723563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: 25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: 5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization
Study: NCT05020418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chart Review
Description: Intervention sites will receive a multi-faceted implementation intervention, which will include external and internal blended facilitation, education materials for providers and patients, and audit and feedback about practices and outcomes with benchmarking to non-intervention sites.
Study: NCT05521841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block(Bilateral Ultrasound Guided Erector Spinae Plane Block)
Description: Bilateral USG guided Erector Spinae Plane Block:~Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg Ultrasound transducer will be placed in a cephalocaudal orientation over the back at 10th thoracic vertebral level.~The probe will then slowly be moved laterally until the transverse process is visible The trapezius muscle and erector spinae muscle will be identified as superficial to the transverse process.~A 25-gauge Quincke spinal needle (Romsons spinal needle, Quincke type)will be inserted using an in-plane approach in the cephalad to the caudal direction and towards the transverse process.~A 5ml bolus of local anesthetic will be given. Erector spinae muscle plane is then visualized separating from the transverse process.~The local anesthetic is then injected in 5 ml increments, with aspiration after every 5 ml to avoid intravascular injection Same procedure will be repeated on the other side

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block(Bilateral Ultrasound-guided bilateral Transversus abdominis plane block)
Description: Bilateral Ultrasound-guided bilateral Transversus abdominis plane block Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg The linear transducer will be placed in the transverse plane at the lateral abdominal wall in the mid-axillary line, between the lower costal margin and the iliac crest.~Abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized.~Bowel movement and visualization of hypoechoic peritoneum would further guide the block.~The needle will be inserted in-plane and advanced until the tip is between the internal oblique and the transversus abdominis muscle.~After negative aspiration, 20 mL of 0.25% bupivacaine is injected in a 5ml increment ,aspirating after every 5ml injection.~Same procedure will be repeated on the other side.
Study: NCT06016439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff partial repair with superior capsular augmentation with LHBBT
Description: Residual rotator cuff defect will be reconstructed using LHBBT.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff partial repair
Description: Rotator cuff will be repaired with remaining residual defect.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic complete rotator cuff repair
Description: Arthroscopic complete repair as a standard procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture anchor(s)
Description: Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture anchor(s)
Description: Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).

Intervention type: DEVICE
Group type: OTHER
Intervention: Suture anchor(s)
Description: Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
Study: NCT06199349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMDTC for injection
Description: GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial
Study: NCT05071274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skinpen Prescision System
Description: Skinpen Precision is an automated nonsurgical micro needling device designed for use by licensed health care practitioners or individuals directed by practitioners. The device incorporates a sterile Microneedle cartridge and Biosheath for single use only.
Study: NCT05126459

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Regimen 1
Description: Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg) In combination with oral drugs stated above, administeration via inhalation of Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regimen #2
Description: Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Meperidine (1.5 -2 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regimen #3
Description: Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Midazolam (0.5- 0.75 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
Study: NCT05853757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zzowin Nutra Tablet
Description: 1 Tablet daily half an hour before going to bed
Study: NCT05476991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75-300mg
Description: Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75-300mg
Description: Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
Study: NCT04976569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN-DBS stimulation pattern change
Description: Deep brain stimulation (DBS) is an elective surgical procedure in which electrodes are implanted into certain brain areas.We use specific STN-DBS stimulation pattern to regulate sleep architecture.
Study: NCT06277154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MASCT-I
Description: The final products of MASCT-I technology are dendritic cells (DC) and effector T cells.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Commercially approved for cancer treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Commercially approved for cancer treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Commercially approved for cancer treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Commercially approved for cancer treatment
Study: NCT06312995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T3DDY01
Description: Digital acquisition of the patient's forearm using Intel RealSense D415 cameras (CE devices certified according to EN/IEC 60825-1 2007 - Safety of Laser product as Class I Laser Devices, i.e., Non-Hazardous Laser Radiation). The patient's arm is placed on a support to allow the plaster nurse to position the wrist at the correct angle needed to treat the fracture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLASTER
Description: Standard treatment plaster for fractures.
Study: NCT05127590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBN-2397
Description: Continuous oral dosing with the RP2D of RBN-2397 (outpatient basis). Pembrolizumab IV infusion over 30 minutes in clinic on Day 1 of each cycle.
Study: NCT05104879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biosketch Card
Description: The experimental group received a biosketch card during rooming, pre-clinician encounter that gave an overview of the midlevel providers qualifications.
Study: NCT06107946

Intervention type: OTHER
Group type: OTHER
Intervention: USD questionnaire
Description: After a baseline screening symptom assessment, all eligible patients with at least 2 simultaneously occurring symptoms with a numeric rating score ≥4 on the 11 point scale on the Utrecht Symptom Diary, will be asked to fill out the Utrecht Symptom Diary during two weeks. In the first week twice daily (morning and evening), in the second week once daily (evening).
Study: NCT04587739

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Surgery with Neoadjuvant stereotactic body radiation therapy
Description: Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).